Biotech

On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a primary focus on bladder cancer treatment regimen. The clinical-stage biotechnology company is focused on developing therapies for oncology and central nervous system conditions, with NDV-01 and...

Bank of America (BofA) Securities initiated coverage on Immix Biopharma Inc. (NASDAQ:IMMX), driven by NXC-201 in AL amyloidosis. AL amyloidosis is a rare plasma cell disorder wherein abnormal plasma cells in the bone marrow overproduce misfolded antibody proteins (light chains). These proteins...

The U.S. FDA on Thursday approved an expanded indication for Merck & Co Inc.’s (NYSE:MRK) Capvaxive, extending its use to children and adolescents ages 2–17 with chronic conditions who have completed a primary pneumococcal vaccine series. The decision makes Capvaxive the only pneumococcal...

Biogen Inc. (NASDAQ:BIIB) on Wednesday agreed to acquire private biotechnology company RayThera Inc. for up to $1 billion. The company looks to further expand its immunology pipeline and broaden its reach into additional disease areas. The deal includes an upfront payment to RayThera shareholders,...

Novocure Ltd. (NASDAQ:NVCR) on Thursday reported topline results from its Phase 3 TRIDENT study. The data showed that starting Tumor Treating Fields (TTFields) therapy during chemoradiation did not significantly improve overall survival compared with initiating the therapy during the maintenance...

Legend Biotech Corp. (NASDAQ:LEGN) stock fell in Thursday’s premarket trading after the cell therapy company priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS. The offering is expected to raise about $226 million before underwriting...

Novo Nordisk A/S (NYSE:NVO) is investigating claims by cyber extortion group FulcrumSec, which alleges it stole more than a terabyte of data from the pharmaceutical company and is considering selling portions of the information after an unsuccessful $25 million ransom demand. FulcrumSec Claims...

GSK plc (NYSE:GSK) and Spero Therapeutics, Inc. (NASDAQ:SPRO) announced on Wednesday that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated urinary tract infections (cUTIs). First Oral Carbapenem Approved For...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. • Adaptive Biotechnologies stock is trending lower. Why are ADPT shares declining? Adaptive Separation Plan Could Sharpen Focus On MRD...

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies. • Jazz Pharmaceuticals stock is showing positive momentum. What’s ahead for JAZZ stock?...

Verastem, Inc. (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive updated results from its RAMP 205 trial, which evaluates the efficacy of its drug combination in treating metastatic pancreatic cancer. The trial demonstrated an 86% overall survival rate at six...

Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment. Durable Responses And T-Cell Activity Highlight Potential Benefit The cancer immunotherapy company announced that three patients who received...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for AXPAXLI. The stock’s decline comes amid a mixed market backdrop, with S&P 500 futures...

uniQure N.V. (NASDAQ:QURE) stock is up during Wednesday’s premarket session as the company announced plans for a Biologics License Application (BLA) submission for AMT-130, a gene therapy treatment for Huntington’s disease. FDA Opens Accelerated Approval Path This news comes following a...

Outlook Therapeutics Inc. (NASDAQ:OTLK) shares are rising in Wednesday premarket trading after the company announced the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA. The FDA acknowledged receipt of the application on Tuesday. If approved, ONS-5010/LYTENAVA...